National Health Act (Pharmaceutical Benefits – Early Supply) Amendment October 2011 - specification under subsection 84AAA(2) (No. PB 73 of 2011)

Overview

The National Health Act 1953 was amended in October 2011 through the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2011. The primary objective of this legislative amendment is to adjust the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, which specifies the pharmaceutical items exempt from Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements for early supplies. The Act was enacted by the Australian Parliament to provide a comprehensive framework for health-related matters in Australia, and this specific amendment aims to address a gap in the existing regulation by updating the list of pharmaceutical items affected by early supply provisions. The amendment was made under the authority of subsection 84AAA(2) of the Act, allowing the Minister to specify pharmaceutical items through legislative instruments. The Pharmaceutical Benefits Advisory Committee (PBAC) played a key role by recommending the inclusion of the specified pharmaceutical item in the amended instrument. This amendment is considered minor and primarily serves to ensure the continued efficacy and relevance of the legislative framework governing pharmaceutical benefits.

Scope and Application

The National Health (Pharmaceutical Benefits – Early Supply) Amendment October 2011 – Specification under Subsection 84AAA(2) amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, which specifies the pharmaceutical items that are in pharmaceutical benefits for which Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements will not apply for early supplies. This legislative instrument made under the National Health Act 1953 aims to insert a new pharmaceutical item and delete an existing one. The Act applies to the Pharmaceutical Benefits Scheme, which provides access to subsidised medicines for Australians, and the changes outlined in this instrument affect the Pharmaceutical Benefits Advisory Committee’s recommendations and the circumstances under which certain pharmaceutical items are supplied. The changes pertain to the administration and supply of specific pharmaceutical items, ensuring that the administration of certain medications is appropriately managed under the PBS. The amendment to the specification under Subsection 84AAA(2) is a minor and machinery change, reflecting recommendations from the PBAC, which includes representatives from various healthcare and economic backgrounds. The instrument comes into effect on 1 October 2011, and is a legislative instrument as defined under the Legislative Instruments Act 2003.

Key Provisions

This legislative instrument, made under subsection 84AAA(2) of the National Health Act 1953 (the Act), amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009). The amendment involves inserting a new pharmaceutical item and deleting an existing one. The changes concern the pharmaceutical item Degarelix, specifically altering its listed form from 'Powder for injection 80 mg (as acetate) with solvent, syringe and needles' to 'Powder for injection 80 mg (as acetate), injection set'. The listed drug, form, manner of administration, maximum quantity or number of units, and maximum number of repeats for this pharmaceutical item remain unchanged, as they are declared and determined under the Act in the National Health (Listing of Pharmaceutical Benefits) Instrument 2010. The Act imposes certain obligations on the parties it governs, particularly those involved in the supply of pharmaceutical benefits. Suppliers must ensure that any supply of a pharmaceutical benefit meeting the criteria outlined in subsection 84AAA(1) is not considered an early supply of a specified pharmaceutical benefit unless it complies with the Act's requirements. This includes verifying that the supply does not fall within the 20-day period after a previous supply and that it does not originate from a prescription made by a hospital. Any breach of the Act’s provisions regarding early supplies of specified pharmaceutical benefits could result in penalties. However, the specific penalties for breaching the Act are not outlined in the explanatory statement. The National Health Act 1953 and related instruments outline the general penalties for non-compliance, which can include fines and other administrative measures. The Pharmaceutical Benefits Advisory Committee (PBAC) plays a critical role in recommending changes to the pharmaceutical items listed under the Act, ensuring that the recommendations are based on expert opinions from various relevant fields. The PBAC’s recommendations are integral to the legislative process, providing a balanced and informed basis for the Minister’s decisions regarding the pharmaceutical benefits specified under the Act.